Company profile: Novian Health
1.1 - Company Overview
Company description
- Provider of proprietary interstitial laser therapy solutions for the focal destruction of breast tumors, including Novilase Breast Therapy, the Interstitial Laser System for breast-conserving procedures, and evidence-generation programs such as the ABLATE Registry and BR-003 clinical trial to support reimbursement and U.S. marketing clearance.
Products and services
- Interstitial Laser System: An ILT-based system engineered for focal destruction of malignant breast tumors in adult women, enabling breast-conserving procedures via controlled heating that precisely ablates targeted tissue
- Novilase Breast Therapy: A patented, minimally invasive laser ablation procedure that uses controlled heating for focal destruction of breast tumors, delivering a breast-conserving alternative to lumpectomy and traditional surgery
- BR-003 Clinical Trial: A confirmatory study architected to collect data supporting U.S. marketing clearance for ILT-enabled focal destruction of malignant breast tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Novian Health
Gilupi
HQ: Germany
Website
- Description: Provider of medical devices and diagnostic solutions for in vivo isolation and analysis of rare circulating cells from blood. Offers GILUPI CellCollector for enriching circulating tumor cells, liquid biopsy sampling, immunofluorescence microscopy, NuPLex technology for RNA detection, and next-generation sequencing for genetic analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilupi company profile →
Totus Medicines
HQ: United States
Website
- Description: Provider of AI/ML-driven small-molecule drug discovery using innovative DNA-encoded covalent libraries. Offers the Totus Platform combining AI/ML, cellular analysis, and covalent chemistry for high-throughput genome-wide screening, plus an oncology pipeline including TOS-358, a PI3Kα inhibitor for breast, colorectal, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Totus Medicines company profile →
Clarient
HQ: United States
Website
- Description: Provider of cancer diagnostic testing and oncology diagnostic services in the United States, partnering with local pathologists and oncologists to bring the standard of care back to their communities, using multiple technologies to clarify complex problems, help diagnose cancer cases, and provide insight.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarient company profile →
CoStim
HQ: United States
Website
- Description: Provider of antibody agents for cancer treatment and urban regeneration, construction, energy, and digital solutions, including the ChorusLife smart human district, general contracting (Impresa Percassi), construction envelope design and manufacturing (Gualini), global energy services (Elmet), and the GSM Platform for sustainable urban transformation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoStim company profile →
Bicara Therapeutics
HQ: United States
Website
- Description: Provider of dual-action cancer therapies combining targeted treatments with tumor modulators. Offers BCA101, a dual-action bifunctional antibody that inhibits EGFR and disables TGF-β at the tumor site, in clinical trials across multiple cancer types; and BCA356, a bispecific antibody targeting CAIX conjugated to attenuated IL-12, with pre-clinical efficacy and potential for limited systemic toxicity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bicara Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Novian Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Novian Health
2.2 - Growth funds investing in similar companies to Novian Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Novian Health
4.2 - Public trading comparable groups for Novian Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →